REVOLADE 25MG
ELTROMBOPAG TABLETS
What it does
Eltrombopag is a medication used to help increase platelet counts in the blood.
Commonly used for: low platelet counts (thrombocytopenia) in certain blood disorders, chronic immune thrombocytopenic purpura (ITP)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:11:10 · updated 2026-08-03 04:11:22
Drug Interactions
15Moderate (2)
Cladribine - increases exposure
Eltrombopag is predicted to increase the exposure to cladribine. Avoid or adjust dose.
Statins - increases exposure
Eltrombopag is predicted to increase the exposure to statins. Monitor and adjust dose.
Unknown (13)
Alpelisib - increases exposure
Eltrombopagispredictedtoincreasetheexposuretoalpelisib. oTheoretical
Berotralstat - increases exposure
Eltrombopagispredictedtoincreasetheexposureto berotralstat.rTheoretical
Eltrombopag - decreases absorption
Oral selenium is predicted to decrease the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after selenium.
Eltrombopag - increases exposure
SSRIs(fluvoxamine)arepredictedtoincreasetheexposureto eltrombopag.oTheoretical
Eltrombopag - decreases absorption
Oral zinc is predicted to decrease the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after zinc. Theoretical Elvitegravir
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About this medicine
Eltrombopag is a medication used to help increase platelet counts in the blood.
What it treats
- low platelet counts (thrombocytopenia) in certain blood disorders
- chronic immune thrombocytopenic purpura (ITP)
How it works
Eltrombopag stimulates the bone marrow to produce more platelets, which are essential for blood clotting.
Who it's for
This medication is for adults and children with conditions that cause low platelet levels.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Eltrombopag
BNF-referencedEltrombopag is a thrombopoietin receptor agonist that stimulates the production of platelets by binding to and activating the thrombopoietin (TPO) receptor. It is primarily used in the treatment of immune thrombocytopenia, particularly in patients who have not responded to other therapies.
Indications
- Chronic immune thrombocytopenic purpura (ITP) in adults refractory to other treatments
- Immune thrombocytopenia in pediatric patients who are refractory to other treatments
Dosage
Children: Refer to the BNF for Children for specific dosing information, as pediatric doses may vary based on age and weight.
Adults: Initially 50 mg once daily, adjusted to achieve a platelet count of 50 x 10^9/litre or more. If the platelet count is not adequate after 4 weeks, treatment should be discontinued.
Mechanism of action
Eltrombopag works by binding to the thrombopoietin receptor, which activates intracellular signaling pathways that lead to increased megakaryocyte proliferation and differentiation. This results in enhanced platelet production in the bone marrow.
Pharmacodynamics
By activating the thrombopoietin receptor, eltrombopag increases platelet counts in patients with low platelet counts due to various conditions, particularly immune thrombocytopenia. The efficacy of the drug is monitored by measuring platelet counts, and dosage adjustments are made based on these counts.
Pharmacokinetics
Eltrombopag is well absorbed after oral administration, with peak plasma concentrations occurring within 2 hours. It has a half-life of approximately 5 to 9 hours and is primarily metabolized by the liver via cytochrome P450 enzymes, notably CYP1A2. Eltrombopag is excreted mainly in the feces, with a small percentage eliminated in urine. The presence of food, particularly high-calcium meals, can reduce its absorption.
Contra-indications
- Hypersensitivity to eltrombopag or any of its components
- Severe hepatic impairment
Adverse effects
- Alopecia
- Anaemia
- Appetite decrease
- Asthenia
- Cough
- Depression
- Diarrhoea
- Dry mouth
- Fever
- Gastrointestinal discomfort
- Haemolytic anaemia
- Hepatic disorders
- Hyperbilirubinaemia
- Increased risk of infection
- Malaise
- Menorrhagia
- Muscle complaints
- Nausea
- Oral disorders
- Peripheral oedema
- QT interval prolongation
- Sleep disorders
- Sweat changes
- Vertigo
- Vision disorders
- Vomiting
Interactions
- Eltrombopag and cladribine: Moderate (increases exposure)
- Eltrombopag and statins: Moderate (increases exposure)
- Eltrombopag and alpelisib: Unknown (increases exposure)
- Eltrombopag and berotralstat: Unknown (increases exposure)
- Eltrombopag and larotrectinib: Unknown (increases exposure)
- Eltrombopag and letermovir: Unknown (increases concentration)
- Eltrombopag and methotrexate: Unknown (increases concentration)
- Oral selenium and eltrombopag: Unknown (decreases absorption)
- SSRIs and eltrombopag: Unknown (increases exposure)
- Eltrombopag and talazoparib: Unknown (increases exposure)
Precautions
- Monitor full blood count, platelet count, and liver function regularly during treatment.
- Monitor serum creatinine, urea, and electrolytes (including potassium, magnesium, and calcium) before and during treatment.
- Consider stopping treatment if there is inadequate response after 3 months.
- Caution in patients with mild to moderate hepatic impairment.
Pregnancy
Manufacturer advises avoiding use due to potential toxicity based on animal studies.
Breast-feeding
Present in milk in animal studies; caution
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Eltrombopag
PubChem CID 135449332Molecular formula: C25H22N4O4
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.